Physician profile
Laura T Buisson
NPI 1760796577
$7,535.47
in general payments reported to CMS, 2019-2025
24 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $306 · 2021: $684 · 2022: $1,481 · 2023: $1,709 · 2024: $1,606 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,422 · Entertainment: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,421.83 |
| Entertainment | $158.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,076.96 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $774.15 | 2022-2025 | Rocklatan, Tryptyr, Total30 |
| Oyster Point Pharma, INC. | $732.34 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $605.36 | 2022-2024 | Alphagan P, Lumigan |
| Allergan, INC. | $534.80 | 2019-2022 | |
| Dompe US, INC. | $516.27 | 2023-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $451.87 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $378.72 | 2024-2025 | Vevye, Natacyn, Tobradex St |
| Sun Pharmaceutical Industries INC. | $377.61 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $317.36 | 2019-2023 | |
| Optos, INC. | $295.73 | 2020-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Carl Zeiss Meditec USA, INC. | $279.39 | 2023 | Cirrus Hd-Oct, Clarus |
| Shire North American Group INC | $234.73 | 2019 | |
| Coopervision INC. | $228.91 | 2022-2025 | Clariti Contact Lens, Biofinity Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $187.96 | 2023-2025 | Miebo, Lotemax Sm, Infuse |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $181.86 | 2024 | Idose |
| Kala Pharmaceuticals, INC. | $117.99 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $92.86 | 2023 | Syfovre |
| Aerie Pharmaceuticals, INC. | $36.07 | 2020 | |
| Ocular Therapeutix, INC. | $28.84 | 2023 | Dextenza |
| Astellas Pharma US INC | $26.60 | 2024 | Izervay |
| Sight Sciences, INC. | $22.68 | 2021 | |
| Biotissue Holdings INC. | $19.16 | 2019 | |
| Eyevance Pharmaceuticals LLC | $17.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Buisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.